tiprankstipranks
Relmada Therapeutics (DE:4E2)
STUTTGART:4E2

Relmada Therapeutics (4E2) Cash flow

0 Followers

Relmada Therapeutics Cash Flow

DE:4E2's free cash flow for Q4 2023 was $-10.25M. For the 2023 fiscal year, DE:4E2's free cash flow was decreased by $52.14M and operating cash flow was $-10.25M. See a summary of the company’s cash flow.
Cash Flow
TTM
Dec 23Dec 22Dec 21Dec 20Jun 19
Operating Cash Flow
$ -74.27M$ -51.66M$ -103.80M$ -91.87M$ -27.81M$ -10.50M
Investing Cash Flow
$ 49.95M$ 50.45M$ 19.73M$ -54.12M$ -34.45M$ 0.00
Financing Cash Flow
$ 311.42K$ -98.46K$ 45.02M$ 187.94M$ 28.47M$ 17.48M
Cash Flow From Discontinued Operation
------
Other Cash Adjustment Inside Changein Cash
------
End Cash Position
$ 45.08M$ 4.09M$ 5.40M$ 44.44M$ 2.50M$ 9.22M
Income Tax Paid Supplemental Data
----$ 0.00$ 0.00
Interest Paid Supplemental Data
----$ 2.42K$ 5.93K
Issuance Of Capital Stock
--$ 42.73M$ 184.64M$ 20.53M$ 17.76M
Issuance Of Debt
--$ -50.00K--$ 0.00
Repayment Of Debt
--$ -50.00K-$ -110.25K$ -285.17K
Free Cash Flow
$ -74.27M$ -51.66M$ -103.80M$ -91.87M$ -27.81M$ -10.50M
Domestic Sales
------
Foreign Sales
------
Currency in USD

Relmada Therapeutics Cash Flow

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis